CAS: 238750-77-1; Cyclopentyl (S)-2-((R)-2-((S)-1-Hydroxy-2-(Hydroxyamino)-2-Oxoethyl)-4-Methylpentanamido)-2-Phenylacetate

该化合物是一种针对多种乳腺的小型分子性天草枯抑制剂,针对的是包括LTA4H(LTA4H)和Aminopotidase N(APN)在内的多种天草原,其主要行动机制是干扰肿瘤细胞的氨基酸新陈代谢,导致蛋白合成受损和诱发聚虫病.Tosedostat由于有能力有选择地在肿瘤组织中蓄积,在血解恶性肿瘤和固态肿瘤方面显示出潜力. 临床和临床研究突出显示了其有利的药动能特征和口服生物利用率. 该化合物对肿瘤生长中的关键酶的双重抑制和免疫调节位置,是进一步进行肿瘤研究的有希望的候选方.

结构式图片

合成工艺路线路线简述

    反应生成他达拉非
    参考文献: Absorbent Article Having Good Body Fit Under Dynamic Conditions[fr] Article Absorbant Epousant Bien Le Corps En Conditions Dynamiques
    标题: Absorbent Article Having Good Body Fit Under Dynamic Conditions[fr] Article Absorbant Epousant Bien Le Corps En Conditions Dynamiques
    摘要:一种具有改进身体贴合度的吸收物品,其中在外部和中央吸收成员中分别使用向下偏转的折痕线和向上偏转的成形线的组合,在裆部区域实现贴合几何形状,同时增强对物品中液体流动的控制.在外部和中央吸收成员之间具有导液屏障的实施例特别有助于实现减少泄漏.

    海关参考信息

    武汉壹加壹生物科技有限公司
    小微企业
    注册号: 91420115MACCW9789M法定代表人:刘明
    注册资本:100万元人民币类型:有限责任公司(自然人投资或控股)
    成立日期:2023-3-17登记机关:武汉市江夏区市场监督管理局
    注册地址: 湖北省武汉市江夏区经济开发区大桥新区邢远长工业园4#楼2楼203
    一般项目:技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广,医学研究和试验发展,生物化工产品技术研发,化工产品销售(不含许可类化工产品),专用化学产品销售(不含危险化学品),合成材料销售,新型催化材料及助剂销售,实验分析仪器销售,技术玻璃制品销售,互联网销售(除销售需要许可的商品),货物进出口,技术进出口,日用百货销售,服装服饰零售,皮革制品销售,化妆品零售,文具用品零售,音响设备销售,五金产品零售,电子产品销售,新材料技术推广服务,新材料技术研发。(除许可业务外,可自主依法经营法律法规非禁止或限制的项目)
    免费会员现货
    http://www.yjybiochem.com
    企业联系电话:166 0273 9303👤
    📞 武汉壹加壹生物科技有限公司 联系方式
    联系人: 向玉田
    手机: 18995604068
    邮箱:673003916@qq.com
    微信 18995604068 | 2140408240
    QQ:2140408240
    ⚠️ 声明: 咨询或交易时请注意风险评估和信息核实,百琢研不参与任何交易。

    地址:湖北省武汉市江夏区经济开发区大桥新区邢远长工业园4#楼2楼203
    常规和库存产品100产品总量: 431
    武汉壹加壹生物科技有限公司logo
    平台资质认证✓营业执照✓
    CAS号:238750-77-1
    中文名:托舍多特
    英文名:Tosedostat
    纯度:99% HPLC1G/5G/1KG
    产品图片备注:现货
    主打产品,生产工厂、精细化学品、医药中间体、材料中间体
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    1. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia By Jenkins, Christopher; Hewamana, Saman; Krige, David; Pepper, Chris; Burnett, Alan From Leukemia Research (2011), 35(5), 677-681. 2. Phase I/II clinical study of tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia By Loewenberg, Bob; Morgan, Gareth; Ossenkoppele, Gert I.; Burnett, Alan K.; Zachee, Pierre; Duehrsen, Ulrich; Dierickx, Daan; Mueller-Tidow, Carsten; Sonneveld, Pieter; Krug, Utz; et al From Journal of Clinical Oncology (2010), 28(28), 4333-4338. 3. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours By van Herpen, C. M. L.; Eskens, F. A. L. M.; de Jonge, M.; Desar, I.; Hooftman, L.; Bone, E. A.; Timmer-Bonte, J. N. H.; Verweij, J. From British Journal of Cancer (2010), 103(9), 1362-1368. 4. Quinazoline derivatives and methods of treatment By Tung, Roger From U.S. Pat. Appl. Publ. (2010), US 20100260674 A1 20101014. 5. Surface topographies for non-toxic bioadhesion control By Brennan, Anthony B.; Long, Christopher James; Bagan, Joseph W.; Schumacher, James Frederick; Spiecker, Mark M. From U.S. Pat. Appl. Publ. (2010), US 20100226943 A1 20100909. 6. Starving to succeed By Davenport, Emma L.; Aronson, Lauren I.; Davies, Faith E. From Autophagy (2009), 5(7), 1052-1054. 7. Gene expression biomarkers of aminopeptidase inhibition in tumor-derived cell lines By Krige, David; Drummond, Alan Hastings From PCT Int. Appl. (2009), WO 2009098451 A2 20090813. 8. A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors By Reid, Alison H. M.; Protheroe, Andrew; Attard, Gerhardt; Hayward, Nikki; Vidal, Laura; Spicer, James; Shaw, Heather M.; Bone, Elizabeth A.; Carter, Joanne; Hooftman, Leon; et al From Clinical Cancer Research (2009), 15(15), 4978-4985. 9. Tosedostat: aminopeptidase inhibitor oncolytic By Owen, R. T.; Castaner, R.; Bolos, J. From Drugs of the Future (2009), 34(2), 115-118. 10. Aminopeptidase inhibition as a targeted treatment strategy in myeloma By Moore, Hannah E.; Davenport, Emma L.; Smith, Emma M.; Muralikrishnan, Srikanth; Dunlop, Alan S.; Walker, Brian A.; Krige, David; Drummond, Alan H.; Hooftman, Leon; Morgan, Gareth J.; et al From Molecular Cancer Therapeutics (2009), 8(4), 762-770. 11. Dosing schedules of leukotriene synthesis inhibitors for human therapy By Hermann, David J.; Hartman, Daniel L.; Van Ess, Peter James; Wang, Wenping From PCT Int. Appl. (2008), WO 2009002746 A1 20081231. 12. CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells By Krige, David; Needham, Lindsey A.; Bawden, Lindsay J.; Flores, Nicolas; Farmer, Hannah; Miles, Lauren E. C.; Stone, Erica; Callaghan, Juliana; Chandler, Stephen; Clark, Vanessa L.; et al From Cancer Research (2008), 68(16), 6669-6679. 13. Preparation of cytostatic hydroxamic acid derivatives of amino acids By Pearson, Lindsey Ann; Ayscough, Andrew Paul; Huxley, Philip; Drummond, Alan From U.S. (2002), US 6462023 B1 20021008. 14. Antibacterial hydroxamic acid derivatives By Hunter, Michael George; Beckett, Raymond Paul; Clements, Martin John; Whittaker, Mark From PCT Int. Appl. (2000), WO 2000044373 A1 20000803. 15. Hydroxamic acid derivatives as inhibitors of beta-amyloid production By Johnstone, Mandy; Ayscough, Andrew Paul From PCT Int. Appl. (2000), WO 2000009119 A1 20000224. 16. Hydroxamic acid derivatives of amino acids as antiinflammatories By Ayscough, Andrew Paul; Whittaker, Mark From PCT Int. Appl. (1999), WO 9940910 A1 19990819. 17. Aminopeptidase N (CD13) as a target for cancer chemotherapy By Wickstrom Malin; Larsson Rolf; Nygren Peter; Gullbo Joachim From Cancer science (2011), 102(3), 501-8.

    合成参考文献


    参考文献:10.1007/s11864-017-0445-5
    摘要:Thomas X, Le Jeune C. Treatment of Elderly Patients With Acute Myeloid Leukemia. Current Treatment Options in Oncology. 2017 Jan 31;18(1):2. doi: 10.1007/s11864-017-0445-5.
    参考文献:10.1021/acs.jmedchem.9b00757
    摘要:Lee J, Vinh NB, Drinkwater N, Yang W, Kannan Sivaraman K, Schembri LS, Gazdik M, Grin PM, Butler GS, Overall CM, Charman SA, McGowan S, Scammells PJ. Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions. J Med Chem. 2019 Aug 08;62(15):7185–209. doi: 10.1021/acs.jmedchem.9b00757.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知